The Trial That Lowered Inflammation Without Touching Cholesterol

Inflammatory markers travel with cardiovascular risk. High-sensitivity C-reactive protein predicts events, and it does so partly independently of cholesterol. What that association could not settle was direction: does inflammation drive atherosclerosis, or is it a downstream signal of arterial damage already underway?

Answering that requires an unusual experiment — a drug that suppresses inflammation while leaving lipids untouched. In 2017, CANTOS delivered exactly that. The trial randomised 10,061 patients who had already had a myocardial infarction and whose hsCRP was at least 2 mg/L, following them for a median of 3.7 years across three doses of canakinumab, a monoclonal antibody targeting interleukin-1β.

The drug did what it was supposed to. hsCRP fell by 26%, 37% and 41% across the three dose arms. LDL cholesterol did not move.

Cardiovascular events fell too — modestly. The primary endpoint rate was 4.50 per 100 person-years on placebo against 3.86 on the 150 mg dose, the only arm to reach statistical significance after adjustment for multiple comparisons. That is a real result, and it is the cleanest available evidence that inflammation is a causal contributor rather than a bystander.

It is also why you have never been offered this drug for heart disease. Fatal infection or sepsis occurred at 0.31 per 100 person-years on canakinumab versus 0.18 on placebo. Suppressing an inflammatory pathway that exists to fight infection has a predictable cost, and in this trial the cost was measured. Canakinumab was not approved for cardiovascular prevention.

The other trial usually cited here, JUPITER, is often misread as inflammation evidence. It randomised 17,802 adults with low LDL-C but elevated hsCRP to rosuvastatin or placebo and reported a hazard ratio of 0.56 — a large effect. But the statin halved LDL cholesterol at the same time as lowering hsCRP, so the design cannot separate the two. It also stopped early, at a median of 1.9 years, which tends to exaggerate effect size.

Taken together, the honest summary is narrow but real: inflammation contributes causally to atherosclerosis, and hsCRP is a genuine risk marker that refines an estimate. It is not established as a treatment target in its own right, and a single elevated value is close to uninterpretable — hsCRP rises with infection, obesity, smoking, autoimmune disease and even recent hard exercise.

Why this matters for tracking: hsCRP is only informative as a trend, and only when the surrounding context is recorded. A value drawn three days after a heavy training block or a head cold means something different from the same value drawn in a settled week. If you log it, log what was happening around it — and interpret a persistent elevation as a prompt for a clinical conversation rather than a number to attack directly.